Wet AMD Care Looks to Cut the Injection Burden
Sponsored·October 30, 2026
Patients with wet age-related macular degeneration often face a demanding treatment schedule, with repeated injections into the eye to hold the disease in check. A new podcast from Scientific American Custom Media examines that burden with Dr. Nadia Waheed, chief medical officer of Ocular Therapeutix.
The conversation focuses on what the current standard of care asks of patients and clinics, and on emerging approaches that could ease the load. One of them is sustained-delivery therapy, which is designed to release treatment over a longer period so patients need fewer visits. The discussion also turns to durability and long-term vision outcomes, the two measures that matter most to people living with the condition.
Readers should keep in mind who produced the episode. It was made for Ocular Therapeutix, the company developing therapies in this area, by Scientific American's custom media division, which operates separately from the magazine's editorial staff. The episode reflects the sponsor's perspective and does not offer an independent evaluation of the therapies it describes.
For anyone following the field, the central question is whether longer-lasting treatments can mean fewer appointments without sacrificing sight. Independent trial data and regulatory decisions will be the best guide to whether these approaches deliver on that promise.